NeuroPace Lifts FY24 Revenue Guidance From $73M - $77M To $76M - $78M, Est $75.899M
Portfolio Pulse from Benzinga Newsdesk
NeuroPace has raised its FY24 revenue guidance from $73M-$77M to $76M-$78M, surpassing the estimated $75.899M. The company expects revenue growth to be driven by increasing sales of its RNS System and higher sales of DIXI Medical stereo EEG products.
August 13, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroPace has increased its FY24 revenue guidance to $76M-$78M, driven by strong sales of its RNS System and DIXI Medical stereo EEG products.
The upward revision in revenue guidance indicates strong sales performance and positive market reception of NeuroPace's products, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100